RxDoctor Payments Data

Janina Kean, APRN

Psychiatric/Mental Health · Farmington, CTNPI 1821447053

Payments from drug & device makers

$930in general payments, 2019–2025

Across 44 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$168
  • Sunovion Pharmaceuticals Inc.$155
  • Axsome Therapeutics, Inc.$150
  • Neurocrine Biosciences, Inc.$82
  • AbbVie$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • plus $229 from 8 others

What the payments were for

  • Food & beverage$88395%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 65th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,902
Medicare patients
36
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,323
VraylarCariprazine Hcl13$38,364
VyvanseLisdexamfetamine Dimesylate13$7,406
Clonazepam242$2,826
Paroxetine ErParoxetine Hcl13$2,122
Aripiprazole40$1,726
Escitalopram Oxalate122$1,325
Ziprasidone Hcl21$1,163
Bupropion XlBupropion Hcl68$1,115
Venlafaxine Hcl ErVenlafaxine Hcl69$1,034
Sertraline Hcl79$785
Duloxetine Hcl35$683
Alprazolam ErAlprazolam16$618
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$596
Lamotrigine64$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$82$101,32312 claims
AbbVieVraylar$78$38,36413 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$48$7,40613 claims
Almatica Pharma LLCSertraline Hcl$19$78579 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →